Healthcare
Travere Therapeutics, Inc.(TVTX)
Live Price
Offline$55.15
+1.87% today
Window Change
+16.89%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $4.08B
- Revenue Growth
- +110.5%
- EPS Growth
- +86.3%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Travere Therapeutics, Inc. (TVTX) is a Healthcare stock with a market cap of $4.08B and listed on NASDAQ. The stock last traded around $55.15 and up 16.9% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +110.5%, EPS growth of +86.3%, a dividend yield of 0.0%. What stands out right now is revenue +110.5%, EPS +86.3%, free cash flow +111.2% with operating margin -12.8% and ROIC -13.9%. Valuation already assumes a fairly strong business story at price/sales 8.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TVTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+110.5% vs +7.6% peer median
Operating Margin
Below sector median
-12.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +110.5% and EPS at +86.3%, with operating margin around -12.8%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TVTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TVTX Max Drawdown
-8.94%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TVTX and SPY.
Company Overview
Travere Therapeutics, Inc.
NASDAQ Global Market
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Leadership
- Eric Dube
- IPO Date
- Nov 8, 2012
- Employees
- 385
- Street Address
- 3611 Valley Centre Drive
- Mailing
- San Diego, CA, 92130
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 888 969 7879
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 194.5
- Price/Sales
- 8.3
- Price/Book
- 34.7
Growth
- Revenue
- +110.5%
- EPS
- +86.3%
- Free Cash Flow
- +111.2%
Profitability
- Gross Margin
- 94.2%
- Operating Margin
- -12.8%
- Net Margin
- -10.2%
- ROE
- -79.2%
- ROIC
- -13.9%
Balance Sheet
- Debt/Equity
- 2.96
- Current Ratio
- 2.74
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.